Completion Rate of Disability Awareness
Improvement Training
ESG
LOTTE Biologics places human rights and safety at the core of all its business activities and continuously advances its standards.
LOTTE Biologics is committed to creating positive impact across customers and society through responsible human rights
management. To support ethical decision-making and responsible conduct across all business activities, the company has established
the LOTTE Biologics Human Rights Charter and actively promotes a culture of respect for human rights.
Human Rights Awareness
LOTTE Biologics recognizes critical importance of human rights management and is intensifying employee training programs to raise awareness on human rights and propagate a culture of respect across the organization. In 2025, the Company provided training on labor and human rights topics for employees, including disability awareness improvement, prevention of sexual harassment, prevention of workplace harassment, and fostering a culture of mutual respect.
Completion Rate of Sexual Harassment
Prevention Training
Completion Rate of Workplace
Harassment Prevention Training
Occupational Health & Safety Strategy
Incident Management
Achieved 0 major incidents and maintained an accident rate of 0.17%
Safety & Health
Management System
100% participation in
job-specific safety training
Community Engagement
Focus on employee participation,
strengthening global transparency and
governance
Incident Management
Dedicated
Organization for Major
Incident Response
LOTTE Biologics established a dedicated HSE team in 2024 to enable proactive and
systematic response to major incidents and strengthen its safety and health
management framework.
The HSE team operates independently from other departments, ensuring professional
expertise and accountability in occupational safety. Through these efforts, the company
aims to prevent major incidents and ensure compliance with regulatory requirements.
Incident Reporting System
LOTTE Biologics operates a structured risk assessment system to proactively manage
safety and environmental risks. In the event of an incident, a clear reporting framework is
in place to enable rapid response.
Reporting and response procedures are defined based on the severity of incidents,
strengthening overall emergency response capabilities.
Reporting Process
Incident
occurrence
Communication with
relevant divisions
relevant divisions
Initial
response
Communication withrelevant divisions
Composition
of Case
Investigation
TF
Case
Investigation
Interview forroot causes
BCP execution
Reporting
Reoccurrenceprevention
measures
Case
closure
Case Investigation Task Force
- Fatality
- Fatality occurring during the course of work due to illness, disaster, or accident
- Lost Time Injury
- Injury resulting in one or more lost workdays due to illness, disaster, or accident
- Restricted Work Case
- Injury requiring treatment at an external medical institution, after which the employee is unable to fully
perform normal duties and can only perform partial work - Medical Treatment Case
- Injury requiring treatment at an external medical institution, after which the employee is able to immediately resume normal duties
Internal Investigation by Division
- First Aid Case
- Injury requiring only minor treatment or treatment with over-the-counter medication
- Near Miss
- Incident in which no injury, illness, or damage occurred but which had the potential to result in harm
(near miss)
Safety & Health Management System
Quality Training & Management System
LOTTE Biologics prioritizes quality management as a core principle of its CDMO operations.
The company operates manufacturing facilities in compliance with global cGMP (Current Good Manufacturing Practice) standards and delivers
high-quality biopharmaceutical products supported by a robust quality system.
The Syracuse Bio Campus has obtained more than 62 approvals from global regulatory authorities, including the FDA, EMA, and PMDA. In 2024,
the site successfully completed FDA and PMDA inspections with zero observations, demonstrating a high level of quality management.
LOTTE Biologics also facilitates systematic cross-training programs to enable knowledge sharing across sites, supporting seamless operational
alignment with the Songdo Bio Campus. The company manages training records and status through an electronic training management system
and operates a structured training framework aligned with different stages of learning objectives.
Supply Chain Management System
LOTTE Biologics requires its partners to uphold standards across environmental protection, human rights, health and safety, quality management,
compliance, ethics, and management systems. All partners are expected to comply with these standards and align with
LOTTE Biologics' ESG principles.
The Code of Conduct is based on globally recognized frameworks, including the UN Global Compact, the UN Guiding Principles on Business and
Human Rights, the OECD Guidelines for Multinational Enterprises, the UN Convention on the Rights of the Child, the ILO Core Conventions, and
the Responsible Business Alliance (RBA) Code of Conduct. Where local regulations differ, the stricter standard is applied.
Supplier Code of Conduct
| Category | Key Areas |
|---|---|
| 1. Environmental Protection | Compliance with applicable laws and regulations; adherence to substance restrictions; assessment of environmental impacts; response to climate change; resource circulation and waste reduction; water resource management; pollution control |
| 2. Human Rights | Prohibition of discrimination; compliance with labor laws and regulations; humane treatment; freedom of association; protection of young workers; prohibition of forced labor |
| 3. Safety Management | Compliance with safety-related laws and regulations; safety inspections and diagnostics; establishment of safety management systems; safety training; management of cafeterias and dormitories |
| 4. Quality Management | Compliance with applicable regulations; establishment of quality management systems; quality performance evaluation; quality training |
| 5. Compliance and Ethical Management | Prohibition of improper or illegal gains; enhancement of management transparency; prevention of unfair trade practices; responsible supply chain management; protection of personal information; protection of intellectual property rights |
| 6. Management Systems | Commitment to sustainable management; risk management |
Supplier Selection and Evaluation
LOTTE Biologics evaluates and manages all Tier 1 suppliers through a comprehensive assessment framework that considers ESG factors,
business criteria, and various risks.
Suppliers are categorized into partners, key partners, and potential partners based on their capabilities and supplied products, enabling
structured and systematic management. ESG criteria are also incorporated into the selection process for new partners to promote responsible
supply chain management.
New Partner
Evaluation
- Verification of supplier suitability in
alignment with LOTTE Biologics'
supply chain management
framework
Regular
Evaluation
- Comprehensive assessment and
grading of selected Key Partners
based on internal criteria - Differentiated benefits such as
long-term contracts provided
according to evaluation grade
Irregular Evaluation /
Post-Management
- Ongoing evaluation of lower-rated
Key Partners to proactively manage
risk and identify improvement tasks - Tracking of corrective actions and
implementation of penalties or
disqualification (delisting) where
applicable
Community Engagement
LOTTE Biologics is advancing its CSR strategy under the core pillars of Health, Environment, and Communities, with a focus on employee
participation.
The company is implementing CSR initiatives in phases—establishing a structured CSR framework (Phase I) and strengthening global
transparency and governance (Phase II). CSR efforts are evolving beyond one-time social contributions into sustainable value creation aligned
with the company's business and ESG strategy.
Through these initiatives, LOTTE Biologics aims to foster a healthy and sustainable ecosystem together with local communities, employees, and
partners.
CSR Vision
Sustainability for Health, Environment and Communities
CSR Strategy
CSR
InternalizationFostering a culture
of employee
participation
2025InternalizationFostering a culture
of employee
participation
CSR
SystemizationEstablishing core themes
and addressing key
social issues
2026SystemizationEstablishing core themes
and addressing key
social issues
CSR
TransparencyPerformance measurement
and alignment with
sustainability standards
2027TransparencyPerformance measurement
and alignment with
sustainability standards
